Diadema Partners LP Summit Therapeutics Inc. Call Options Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
Call Options
1 transactions
Others Institutions Holding SMMT
# of Institutions
231Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$563 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$269 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$182 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$151 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$129 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.64B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...